Abstract
This study provides novel estimates of Chinese policymakers' WTP per QALY specifically in end-of-life contexts involving common and rare diseases, highlighting the significant impact of disease rarity on reimbursement decisions. These findings offer empirical support for adopting differentiated cost-effectiveness thresholds tailored to end-of-life treatments based on disease rarity in China.
Introduction
National health systems face the persistent challenge of allocating finite resources across diverse medical needs. Central to this challenge is the determination of cost-effectiveness thresholds—the maximum amount a system is willing to pay for one unit of health gain, typically measured as a Quality-Adjusted Life Year (QALY). Treatments for rare diseases, particularly in end-of-life scenarios, often fail standard cost-effectiveness tests due to high research and development costs and small patient populations. While many Western nations have adopted flexible thresholds for such cases, empirical data on the preferences of Chinese policymakers has remained scarce. This study aims to quantify the premium Chinese decision-makers place on rare disease treatments compared to common ones at the end of life.
Methodology
The researchers employed a contingent valuation study, a survey-based economic technique designed to price non-market resources. The study specifically targeted the actual decision-makers: experts appointed to the National Reimbursement Drug List (NRDL) Expert Committee of China’s National Healthcare Security Administration (NHSA).
Participants were presented with two hypothetical scenarios involving a drug that extends a patient's life by exactly one year in perfect health (1 QALY) before death. Scenario 1 involved a common life-threatening disease, while Scenario 2 involved a rare life-threatening disease. The study utilized single-bounded dichotomous-choice questions, where participants were asked to approve coverage at various ascending price points (bids) until a "no" response was elicited.
The primary dataset was collected through interviews with 99 high-level Chinese policymakers between May and July 2023. This sample represents an 82.5% response rate from the total population of 120 national-level experts responsible for reimbursement decisions, ensuring high representativeness.
Results and Analysis
The analysis revealed a clear and statistically significant preference for funding rare disease treatments over common ones ($p < 0.001$).
- Common Diseases: The estimated Willingness-To-Pay (WTP) per QALY ranged from CNY 78,031 to CNY 126,449, approximately 0.98 to 1.58 times China's 2022 GDP per capita.
- Rare Diseases: The WTP per QALY was substantially higher, ranging from CNY 183,392 to CNY 219,691, or approximately 2.29 to 2.75 times the GDP per capita.
The "rarity premium"—the difference in WTP between the two scenarios—was calculated to be between 1.17 and 1.32 times the GDP per capita (exceeding CNY 100,000 per QALY). Interestingly, demographic analysis showed that female policymakers and those with specific expertise in pharmacoeconomics tended to exhibit higher WTP values in common disease scenarios.
Discussion and Policy Implications
These findings suggest that Chinese policymakers do not view all QALYs as equal; rarity triggers a higher valuation, reflecting an implicit prioritization of equity and compassion over strict economic efficiency. Unlike studies that survey the general public to find "demand-side" thresholds, this research captures a "supply-side" threshold grounded in the real-world budget constraints and opportunity costs managed by NHSA experts.
The results provide strong empirical justification for moving away from a universal, one-size-fits-all cost-effectiveness threshold in China. Instead, the data supports a tiered system where rare, end-of-life treatments are evaluated against a more flexible financial benchmark.
Limitations and Future Research
While highly representative of national decision-makers, the sample size remains modest. The single-bounded survey format and constant disease severity in the scenarios may not capture the full complexity of how various equity factors interact. Future research should consider discrete choice experiments to weigh multiple attributes simultaneously—such as disease severity, age of onset, and the risk of catastrophic health expenditures—while explicitly incorporating future medical costs into the economic models.
Summary updated